Core Viewpoint - Haosen Pharmaceutical reported a revenue of 242 million yuan for the first half of 2025, marking a year-on-year growth of 14.93%, and a net profit attributable to shareholders of 60.79 million yuan, up 4.74% year-on-year [1] Financial Performance - Revenue for the reporting period reached 242 million yuan, reflecting a year-on-year increase of 14.93% [1] - Net profit attributable to shareholders was 60.79 million yuan, showing a year-on-year growth of 4.74% [1] Product and Market Development - The company’s main products include chemical pharmaceutical raw materials and intermediates, which are crucial components of the pharmaceutical manufacturing industry [1] - There is a strong market demand for the company’s main products, with sufficient orders leading to a favorable supply-demand situation [1] - The company is optimizing production capacity to ensure stable supply and is actively enhancing its market development efforts in regions such as the Americas and Europe [1] Research and Development - Haosen Pharmaceutical maintains a high level of investment in research and development, with R&D expenses amounting to 17.71 million yuan, which is 7.32% of its revenue, representing a year-on-year increase of 52.83% [1] - As of the end of the reporting period, the company has 17 products under research, including raw materials, intermediates, and formulation products [1]
海森药业上半年营收增长15%全球化拓展与研发创新助力未来发展